plasma cfdna concentration Search Results


plasma cfdna concentration  (NEN Life Science)
90
NEN Life Science plasma cfdna concentration
Plasma <t>cfDNA</t> concentration ( A ), cfDNA <t>Alu</t> <t>hypomethylation</t> ( B ), and LINE-1 cfDNA integrity ( C ) in the healthy control group (green) and patients with metastatic NEN (grey). Deceased patients are marked in red, patients lost to follow-up in black. * p < 0.05; ** p < 0.005 in the Mann–Whitney U-test.
Plasma Cfdna Concentration, supplied by NEN Life Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plasma+cfdna+concentration/plasma+cfdna+concentration/pmc08870292-173-4-12
Average 90 stars, based on 1 article reviews
plasma cfdna concentration - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Plasma cfDNA concentration ( A ), cfDNA Alu hypomethylation ( B ), and LINE-1 cfDNA integrity ( C ) in the healthy control group (green) and patients with metastatic NEN (grey). Deceased patients are marked in red, patients lost to follow-up in black. * p < 0.05; ** p < 0.005 in the Mann–Whitney U-test.

Journal: Cancers

Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias

doi: 10.3390/cancers14041025

Figure Lengend Snippet: Plasma cfDNA concentration ( A ), cfDNA Alu hypomethylation ( B ), and LINE-1 cfDNA integrity ( C ) in the healthy control group (green) and patients with metastatic NEN (grey). Deceased patients are marked in red, patients lost to follow-up in black. * p < 0.05; ** p < 0.005 in the Mann–Whitney U-test.

Article Snippet: In conclusion, we found plasma cfDNA concentration, integrity, and hypomethylation in metastatic NEN patients to be very promising and easy to assess parameters for a “liquid biopsy” to evaluate patients with neuroendocrine neoplasms during the course of their disease.

Techniques: Clinical Proteomics, Concentration Assay, Control, MANN-WHITNEY

Plasma cfDNA concentration ( A ), cfDNA hypomethylation ( B ), and cfDNA integrity ( C ) with respect to tumor burden (no tumor, low, moderate, or high tumor burden) * p < 0.05.; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

Journal: Cancers

Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias

doi: 10.3390/cancers14041025

Figure Lengend Snippet: Plasma cfDNA concentration ( A ), cfDNA hypomethylation ( B ), and cfDNA integrity ( C ) with respect to tumor burden (no tumor, low, moderate, or high tumor burden) * p < 0.05.; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

Article Snippet: In conclusion, we found plasma cfDNA concentration, integrity, and hypomethylation in metastatic NEN patients to be very promising and easy to assess parameters for a “liquid biopsy” to evaluate patients with neuroendocrine neoplasms during the course of their disease.

Techniques: Clinical Proteomics, Concentration Assay

Receiver operating characteristic (ROC) curves to distinguish between healthy controls and patients with advanced NEN disease ( A ) and between presumably cured NEN patients and patients with advanced NEN ( B ) for cfDNA concentration ( left ), percentage of cfDNA hypomethylation ( middle ), and cfDNA integrity ( right ).

Journal: Cancers

Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias

doi: 10.3390/cancers14041025

Figure Lengend Snippet: Receiver operating characteristic (ROC) curves to distinguish between healthy controls and patients with advanced NEN disease ( A ) and between presumably cured NEN patients and patients with advanced NEN ( B ) for cfDNA concentration ( left ), percentage of cfDNA hypomethylation ( middle ), and cfDNA integrity ( right ).

Article Snippet: In conclusion, we found plasma cfDNA concentration, integrity, and hypomethylation in metastatic NEN patients to be very promising and easy to assess parameters for a “liquid biopsy” to evaluate patients with neuroendocrine neoplasms during the course of their disease.

Techniques: Concentration Assay

Multiparametric ROC analysis using plasma cfDNA concentration, percentage of cfDNA hypomethylation, and cfDNA integrity to estimate the strength of the model to discriminate between ( A ) healthy controls and NEN patients with advanced disease or between ( B ) presumably cured NEN patients and patients with advanced NEN disease.

Journal: Cancers

Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias

doi: 10.3390/cancers14041025

Figure Lengend Snippet: Multiparametric ROC analysis using plasma cfDNA concentration, percentage of cfDNA hypomethylation, and cfDNA integrity to estimate the strength of the model to discriminate between ( A ) healthy controls and NEN patients with advanced disease or between ( B ) presumably cured NEN patients and patients with advanced NEN disease.

Article Snippet: In conclusion, we found plasma cfDNA concentration, integrity, and hypomethylation in metastatic NEN patients to be very promising and easy to assess parameters for a “liquid biopsy” to evaluate patients with neuroendocrine neoplasms during the course of their disease.

Techniques: Clinical Proteomics, Concentration Assay

ROC analysis of plasma cfDNA concentration ( A , B ), Alu hypomethylation ( C , D ), and LINE-1 integrity ( E , F ) for distinguishing healthy controls ( A , C , E ), or cured patients ( B , D , F ) from patients with low, moderate, and high tumor burden (TB), along with the area under the curve (AUC), for sensitivities and specificities see .

Journal: Cancers

Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias

doi: 10.3390/cancers14041025

Figure Lengend Snippet: ROC analysis of plasma cfDNA concentration ( A , B ), Alu hypomethylation ( C , D ), and LINE-1 integrity ( E , F ) for distinguishing healthy controls ( A , C , E ), or cured patients ( B , D , F ) from patients with low, moderate, and high tumor burden (TB), along with the area under the curve (AUC), for sensitivities and specificities see .

Article Snippet: In conclusion, we found plasma cfDNA concentration, integrity, and hypomethylation in metastatic NEN patients to be very promising and easy to assess parameters for a “liquid biopsy” to evaluate patients with neuroendocrine neoplasms during the course of their disease.

Techniques: Clinical Proteomics, Concentration Assay

Multiparametric ROC analysis using cfDNA concentration, percentage of Alu hypomethylation, and LINE-1 integrity to estimate the strength of the model to discriminate between ( A ) healthy controls and NEN patients or ( B ) presumably cured NEN patients and patients with low, moderate, and high tumor burden (TB), along with the area under the curve (AUC), for sensitivities and specificities see .

Journal: Cancers

Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias

doi: 10.3390/cancers14041025

Figure Lengend Snippet: Multiparametric ROC analysis using cfDNA concentration, percentage of Alu hypomethylation, and LINE-1 integrity to estimate the strength of the model to discriminate between ( A ) healthy controls and NEN patients or ( B ) presumably cured NEN patients and patients with low, moderate, and high tumor burden (TB), along with the area under the curve (AUC), for sensitivities and specificities see .

Article Snippet: In conclusion, we found plasma cfDNA concentration, integrity, and hypomethylation in metastatic NEN patients to be very promising and easy to assess parameters for a “liquid biopsy” to evaluate patients with neuroendocrine neoplasms during the course of their disease.

Techniques: Concentration Assay